How AbbVie’s Humira Still Reigns, Despite New Competition. Quarterly revenue for blockbuster arthritis drug declines, largely because of discounts for middlemen. By . David Wainer. Share.

FILE - Packaging for AbbVie's drug, Humira, is photographed in Houston on July 18, 2014. Patients who take the autoimmune disease treatment may see some price relief when several lower-cost ...

Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s (ABBV.N), opens new tab blockbuster arthritis drug Humira this year, but the cost savings are ...

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. But lower ...

An illustration of the packaging for Amgen Inc's Amjevita as well as the 40 milligram auto injector containing a bio similar version of AbbVie's Inc's Humira ...

Sales of AbbVie’s blockbuster drug Humira peaked at $18.9bn last year and, according to analysts at Evaluate Pharma, the product is expected to generate $15.2bn through to 2024. These figures ...

A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by building up a "thicket" of patents related to its blockbuster arthritis drug Humira.

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. But lower pharmacy… ...

AbbVie’s precursor, Abbott Laboratories, launched Humira in 2003 at $522 per two-week 40-milligram syringe. Within 10 years, that price jumped to $1,024 per syringe, according to a House ...

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings? Lowering drug prices for ...